deltatrials
Terminated PHASE1/PHASE2 INTERVENTIONAL 2-arm NCT02937675

A Phase 1-2 Dose-Escalation and Cohort-Expansion Study of Oral Tomivosertib (eFT-508) in Subjects With Hematological Malignancies

Sponsor: Effector Therapeutics

Conditions Lymphoma
Interventions Tomivosertib (eFT-508)
Updated 15 times since 2017 Last updated: Oct 30, 2020 Started: Feb 8, 2017 Primary completion: Nov 12, 2018 Completion: Apr 4, 2019
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

patient recruitment

Other terminated trials from Effector Therapeutics

See all terminations from Effector Therapeutics

Other Lymphoma trials with similar outcome

Browse all Lymphoma trials

This PHASE1/PHASE2 trial investigates Lymphoma and is currently terminated or withdrawn. Effector Therapeutics leads this study, which shows 15 recorded versions since 2017 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Apr 2017 · 59 days · monthly snapshot~Apr 2017 – ~Jan 2018 · 9 months · monthly snapshot~Jan 2018 – ~Jun 2018 · 5 months · monthly snapshot~Jun 2018 – ~Aug 2018 · 2 months · monthly snapshot~Aug 2018 – ~Sep 2018 · 31 days · monthly snapshot~Sep 2018 – ~Oct 2018 · 30 days · monthly snapshot~Oct 2018 – ~Dec 2018 · 2 months · monthly snapshot~Dec 2018 – ~Jan 2019 · 31 days · monthly snapshot~Jan 2019 – ~Aug 2019 · 7 months · monthly snapshot~Aug 2019 – ~Dec 2020 · 16 months · monthly snapshot~Dec 2020 – ~Jan 2021 · 31 days · monthly snapshot~Jan 2021 – ~Jul 2024 · 42 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – present · 22 months · monthly snapshot

Change History

15 versions recorded

  1. Sep 2024 — Present [monthly]

    Terminated PHASE1/PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE1/PHASE2

    Phase: PHASE1_PHASE2 → PHASE1/PHASE2

  3. Jan 2021 — Jul 2024 [monthly]

    Terminated PHASE1_PHASE2

  4. Dec 2020 — Jan 2021 [monthly]

    Terminated PHASE1_PHASE2

  5. Aug 2019 — Dec 2020 [monthly]

    Terminated PHASE1_PHASE2

▶ Show 10 earlier versions

  1. Jan 2019 — Aug 2019 [monthly]

    Terminated PHASE1_PHASE2

    Status: Recruiting → Terminated

  2. Dec 2018 — Jan 2019 [monthly]

    Recruiting PHASE1_PHASE2

  3. Oct 2018 — Dec 2018 [monthly]

    Recruiting PHASE1_PHASE2

  4. Sep 2018 — Oct 2018 [monthly]

    Recruiting PHASE1_PHASE2

  5. Aug 2018 — Sep 2018 [monthly]

    Recruiting PHASE1_PHASE2

  6. Jun 2018 — Aug 2018 [monthly]

    Recruiting PHASE1_PHASE2

  7. Jan 2018 — Jun 2018 [monthly]

    Recruiting PHASE1_PHASE2

  8. Apr 2017 — Jan 2018 [monthly]

    Recruiting PHASE1_PHASE2

  9. Feb 2017 — Apr 2017 [monthly]

    Recruiting PHASE1_PHASE2

  10. Jan 2017 — Feb 2017 [monthly]

    Recruiting PHASE1_PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Effector Therapeutics
Data source: Effector Therapeutics

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations